Increased Risk for Arthritis and Lupus Tied to new Gene
Scientists identify a critical gene that increases a person’s risk for rheumatoid arthritis and systemic lupus and may be involved in other autoimmune diseases.
Celera to Acquire Berkeley HeartLab
Acquisition provides Celera with CLIA-certified laboratory to commercialize its portfolio of new tests & vehicle to deliver personalized disease management in cardiovascular disease.
Philips and the Institute of Health Sciences Join Forces in Molecular Medicine
Royal Philips Electronics and IHS will create new solutions for the early diagnosis of disease and for monitoring the effectiveness of subsequent treatment.
Agendia Raises €25 Million and Receives Second FDA Clearance
ING, one of the largest bank-insurers, becomes a shareholder of Agendia.
Ipsogen Grants Exclusive License to Warnex to Market a Leukemia Molecular Diagnostic Service in Canada
Ipsogen grants Warnex exclusive rights to market a service for the diagnosis and the classification of a group of leukemias.
BSD Medical Obtains Patent License for Primary Breast Cancer Treatment System from Duke University
BSD Medical gains exclusive rights to Duke’s treatment system for primary breast cancer using hyperthermia therapy.
A Study by the MUHC and McGill University Opens a new Door to Understanding Cancer
Study provides a key to understand the mechanisms that trigger cancer cell growth that may prove crucial to develop more targeted treatments for cancer.
GeneNews Secures $2 Million for Development of Prostate Biomarkers
GeneNews signs agreement with an Asian Biomedical consortium to develop blood-based biomarkers for the detection and management of prostate diseases.
Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia into Clinical Practice
Xenomics’ diagnostic test developed for stratification of patients with AML has been implemented at CLIA approved BRT Laboratories.
Eden Biodesign and the University of Manchester Intellectual Property Limited Develop Innovative Treatment for Cancer
UMIP selects Eden Biodesign to provide a range of services for the development of therapeutic for treatment of macular degeneration and cancer.